Molecular epidemiological surveillance of markers for antimarial drugs in Plasmodium falciparum isolates imported to Barcelona, Spain;Vigilancia epidemiológica mediante marcadores moleculares de resistencia frente a antimaláricos en aislados de Plasmodium falciparum importados a Barcelona, España

Medicina Clinica

Volumn 125, Issue 8, 2005, Pages 286-289

  Gascón, Joaquim ^a   Mayor, Alfredo ^a   Mühlberger, Nikolai ^b   Peyerl Hoffmann, Gabriele ^c   Oliveira, ^a   Dobaño, Carlota ^a   Jelinek, Tomas ^b   Corachan, Manuel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Malaria; PCR; Plasmodium falciparum; Resistance

Indexed keywords

ANTIMALARIAL AGENT; CYTOCHROME B;

ARTICLE; CODON; ENDEMIC DISEASE; GENE MUTATION; HEALTH SURVEY; HUMAN; MALARIA; MOLECULAR BIOLOGY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; SPAIN; TRAVEL; TROPICAL MEDICINE;

EID: 26844487009     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078421     Document Type: Article

References (30)

1. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998;321:689-97.
2. Bjorkman A, Phillips-Howard PA. Drug-resistant malaria: mechanisms of development and inferences for malaria control. Trans R Soc Trop Med Hyg. 1990;84:323-4.
3. a serie, n.° 52. 25 Diciembre; 2002. p. 385-6.
4. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress towards targets based on verbal autopsy. Lancet Infect Dis. 2003;3:349-58.
5. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861-71.
6. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA. 1994;91: 1143-7.
7. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209-18.
8. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis. 2004;190:1541-6.
9. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17:582-8.
10. Jelinek T, Pröll S, Hess F, Von Sonnenburg F, Kabagambe K, Löscher T, et al. Geographical differences in the sentivity of polymerase chain reaction for detection of P. falciparum infection in Uganda. Am J Trop Med Hyg. 1996;55:647-51.
11. Alifrangis M, Lemnge MM, Ronn AM, Segeja MD, Magesa SM, Khalil IF, et al. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am J Trop Med Hyg. 2003;69:238-43.
12. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369-74.
13. Velasco M, Gascon J, Valls ME, Vilella A, Corachan M. Paludismo importado del Senegal: a propósito de 17 casos en el año 2000. Med Clin (Barc). 2005;124:19-21.
14. Sánchez C, Lanzer M. Changing ideas on chloroquine in Plasmodium falciparum. Curr Opin Infect Dis. 2000;13:653-8.
15. Basco LK. Molecular epidemiology of malaria in Cameroon. XII. In vitro drug assays and molecular surveillance of chloroquine and proguanil resistance. Am J Trop Med Hyg. 2002;67:383-7.
16. Mayor AG, Gómez-Olive X, Aponte JJ, Casimiro S, Mabunda S, Dgedge M, et al. Prevalence of the K76T mutation in the putative Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene and its relation to chloroquine resistance in Mozambique. J Infect Dis. 2001;183: 1413-6.
17. Pérez-Rosado J, Gervais GW, Ferrer-Rodríguez I, Peters W, Serrano AE. Plasmodium berghei: analysis of the gamma-glutamylcysteine synthetase gene in drug-resistant lines. Exp Parasitol. 2002;101:175-82.
18. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257-63.
19. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S, et al. Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers. J Infect Dis. 2001;183:789-95.
20. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403:906-9.
21. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001;358:1218-23.
22. East African Network for Monitoring Antimalarial Treatment (EANMAT). The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003;8:860-7.
23. Alifrangis M, Enosse S, Khalil IF, Tarimo DS, Lemnge MM, Thompson R, et al. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. Am J Trop Med Hyg. 2003;69:601-6.
24. Wichmann O, Jelinek T, Peyerl-Hoffmann G, Muhlberger N, Grobusch MP, Gascon J, et al. Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malar J. 2003;2:17.
25. Nzila AM, Mberu EK, Sulo J, Cayo H, Winstanley PA, Sibley CH, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother. 2000;44:991-6.
26. Plowe CV, Cortese JF, Djimde A, Nwanyamvu OC, Watkins WM, Winstanley PA, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiological patterns of pyrimetha-mine- sulfadoxine use and resistance. J Infect Dis. 1997;176:1590-6.
27. Kublin J, Dzinjalamala F, Kamwendo D, Malkin E, Cortese J, Martino L, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185: 380-8.
28. Young MD, Burgess RW. Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ. 1959;20:27-36.
29. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother. 2001;45:3122-7.
30. Leartsakulpanich U, Imwong M, Pukrittayakamee S, White NJ, Snounou G, Sirawaraporn W, et al. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol. 2002;119:63-73.